Head to Head Analysis: Invivo Therapeutics (NVIV) & Hologic (HOLX)
Invivo Therapeutics (NASDAQ: NVIV) and Hologic (NASDAQ:HOLX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.
This table compares Invivo Therapeutics and Hologic’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
12.8% of Invivo Therapeutics shares are owned by institutional investors. Comparatively, 97.7% of Hologic shares are owned by institutional investors. 3.9% of Invivo Therapeutics shares are owned by company insiders. Comparatively, 0.8% of Hologic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Invivo Therapeutics and Hologic’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Invivo Therapeutics||N/A||N/A||-$23.43 million||($0.85)||-0.87|
|Hologic||$3.06 billion||3.96||$755.50 million||$2.64||16.66|
Hologic has higher revenue and earnings than Invivo Therapeutics. Invivo Therapeutics is trading at a lower price-to-earnings ratio than Hologic, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Invivo Therapeutics has a beta of 3.22, meaning that its stock price is 222% more volatile than the S&P 500. Comparatively, Hologic has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.
This is a summary of current ratings and target prices for Invivo Therapeutics and Hologic, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Invivo Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 710.81%. Hologic has a consensus price target of $48.64, suggesting a potential upside of 10.60%. Given Invivo Therapeutics’ higher possible upside, equities research analysts clearly believe Invivo Therapeutics is more favorable than Hologic.
Hologic beats Invivo Therapeutics on 11 of the 14 factors compared between the two stocks.
About Invivo Therapeutics
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.
Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.